No 01 2023
Updated: January 31, 2025, 09:21 am
Published: February 1, 2023
Updated: January 31, 2025, 09:21 am
Published: February 1, 2023
Top stories
Collaboration – November 10, 2026
Mendus has been granted SEK 977,300 by Vinnova to establish manufacturing of memory NK cell therapies with its partner NorthX Biologics, alongside the ongoing large-scale production of its lead candidate vididencel.
Intellectual Property – November 10, 2026
The US Patent and Trademark Office has granted Medivir a patent covering fostrox in combination with lenvatinib for liver cancer, with protection now running until at least January 2044, almost three years longer than previously communicated.
Clinical Trials – November 10, 2026
Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.
Pharma Business – November 10, 2026
The European Commission has approved an expanded label for Oncopeptides’ Pepaxti (melflufen) in multiple myeloma. The drug can now be used in adults who have received at least two prior lines of therapy and whose disease is refractory to lenalidomide and the last line of therapy.
Related posts
This site uses cookies